Next to long-established endocrine therapy options (based, e.g., on ESR or aromatase inhibitors) the CDK4/6 targeting, primarily with abemaciclib, became an additional mainstay for the treatment of luminal BC. Here, CYP19A1 is linked to breast cancer.